<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00076934</url>
  </required_header>
  <id_info>
    <org_study_id>DAIT ITN006AI</org_study_id>
    <secondary_id>NMS02</secondary_id>
    <nct_id>NCT00076934</nct_id>
  </id_info>
  <brief_title>Safety of RG2077 in Patients With Multiple Sclerosis</brief_title>
  <official_title>A Phase I Study: Safety of RG2077 (CTLA4-IgG4m) in Patients With Relapsing-Remitting Multiple Sclerosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institute of Allergy and Infectious Diseases (NIAID)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Immune Tolerance Network (ITN)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Repligen Corporation</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>National Institute of Allergy and Infectious Diseases (NIAID)</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Multiple sclerosis (MS) is an autoimmune disorder. In this disease, the body's immune system
      attacks and destroys the cells that cover and protect nerves. This study will test the safety
      of a new drug called RG2077 that is designed to treat MS. The study will not determine
      whether RG2077 is effective in treating MS, only whether it is safe to use in patients with
      MS.

      Study hypothesis: RG2077 will arrest MS if administered early in the course of MS and
      decrease accumulation of lesions on MRI.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Effective treatment of autoimmune disorders is likely to arise not from improved
      immunosuppression, but from improved understanding of the normal mechanisms that generate and
      maintain self-tolerance. RG2077 may block a T cell costimulation pathway central to the
      pathophysiology of MS. A total of 20 patients with MS will be enrolled in this study. Each
      patient participates in the study for 4 months.

      The dose-escalation portion of this study evaluated the safety of a single infusion of RG2077
      (CTLA4-IgG4m) in 16 patients with MS and is now complete. Patients who participated in the
      single infusion portion of the study were assigned to one of four groups. Each group received
      a different dose of RG2077. The second portion of the study will evaluate the safety of 4
      doses of RG2077 in 4 additional patients. In the multiple infusion portion of the study, all
      patients will receive the same dose of RG2077. Patients will be monitored for possible side
      effects of RG2077.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2003</start_date>
  <completion_date type="Actual">February 2006</completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety assessment including a MRI, neurological and physical examinations</measure>
    <time_frame>Throughout study</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of gadolinium (GD) enhancing lesions and T2 lesion volume on MRI</measure>
    <time_frame>Throughout study</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Multiple Sclerosis</condition>
  <condition>Multiple Sclerosis, Relapsing-Remitting</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants receive Regimen 1 for 4 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants receive Regimen 2 for 4 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants receive Regimen 3 for 4 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants receive Regimen 4 for 4 months</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>RG2077 (CTLA4-IgG4m)</intervention_name>
    <description>RG2077</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
    <arm_group_label>3</arm_group_label>
    <arm_group_label>4</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria

          -  Confirmed diagnosis of MS, defined as an MRI consistent with MS plus two separate
             clinical events, or one clinical event and MRI consistent with demyelination plus a
             second MRI demonstrating new lesions

          -  Have declined all FDA approved therapies for MS
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Samia J. Khoury, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Brigham and Women's Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Brigham and Women's Hospital/Harvard Medical School</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.niaid.nih.gov/</url>
    <description>National Institute of Allergy and Infectious Diseases (NIAID) website</description>
  </link>
  <link>
    <url>https://www.niaid.nih.gov/about/dait</url>
    <description>Division of Allergy, Immunology, and Transplantation (DAIT) website</description>
  </link>
  <link>
    <url>http://www.immunetolerance.org</url>
    <description>Immune Tolerance Network (ITN) website</description>
  </link>
  <results_reference>
    <citation>Viglietta V, Bourcier K, Buckle GJ, Healy B, Weiner HL, Hafler DA, Egorova S, Guttmann CR, Rusche JR, Khoury SJ. CTLA4Ig treatment in patients with multiple sclerosis: an open-label, phase 1 clinical trial. Neurology. 2008 Sep 16;71(12):917-24. doi: 10.1212/01.wnl.0000325915.00112.61.</citation>
    <PMID>18794494</PMID>
  </results_reference>
  <verification_date>March 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 6, 2004</study_first_submitted>
  <study_first_submitted_qc>February 6, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 9, 2004</study_first_posted>
  <last_update_submitted>March 23, 2017</last_update_submitted>
  <last_update_submitted_qc>March 23, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 27, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Ataxia</keyword>
  <keyword>MRI</keyword>
  <keyword>MS</keyword>
  <keyword>CTLA4-IgG4m</keyword>
  <keyword>Costimulatory Signals</keyword>
  <keyword>Autoimmune Disorders</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sclerosis</mesh_term>
    <mesh_term>Multiple Sclerosis</mesh_term>
    <mesh_term>Multiple Sclerosis, Relapsing-Remitting</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Immunoglobulin G</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Participant level data and additional relevant materials are available to the public in: 1.) the Immunology Database and Analysis Portal (ImmPort), a long-term archive of clinical and mechanistic data from DAIT-funded grants and contracts; and 2.) TrialShare, the Immune Tolerance Network (ITN) Clinical Trials Research Portal.</ipd_description>
  </patient_data>
  <study_docs>
    <study_doc>
      <doc_id>SDY661</doc_id>
      <doc_type>Individual Participant Data Set</doc_type>
      <doc_url>http://www.immport.org/immport-open/public/study/study/displayStudyDetail/SDY661</doc_url>
      <doc_comment>ImmPort study identifier is SDY661</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>SDY661</doc_id>
      <doc_type>Study protocol synopsis, -summary, -design, -adverse events, -medications,-demographics, - lab tests, -files</doc_type>
      <doc_url>http://www.immport.org/immport-open/public/study/study/displayStudyDetail/SDY661</doc_url>
      <doc_comment>ImmPort study identifier is SDY661</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>ITN006AI/NMS02</doc_id>
      <doc_type>Individual Participant Data Set</doc_type>
      <doc_url>http://www.itntrialshare.org/project/Studies/ITN006AIPUBLIC/Study%20Data/begin.view?</doc_url>
      <doc_comment>TrialShare is a clinical trials research portal developed by the Immune Tolerance Network (ITN) that makes data from the consortium's clinical trials publicly available.</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>ITN006AI/NMS02</doc_id>
      <doc_type>Study protocol synopsis; -schedule of assessments; data and reports; adverse event(s); -specimens availability; -manuscripts and abstracts</doc_type>
      <doc_url>http://www.itntrialshare.org/project/Studies/ITN006AIPUBLIC/Study%20Data/begin.view?</doc_url>
      <doc_comment>TrialShare is a clinical trials research portal developed by the Immune Tolerance Network (ITN) that makes data from the consortium's clinical trials publicly available.</doc_comment>
    </study_doc>
  </study_docs>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

